A First-In-Human, Phase 1 Study Evaluating Oral TACC3 PPI Inhibitor, AO-252, in Advanced Solid Tumors With or Without Brain Metastases

Clinical trial NCT06136884 · RECRUITING

Trial details

NCT number: NCT06136884
Sponsor: A2A Pharmaceuticals Inc.
Status: RECRUITING
Phase: Phase 1
Study type: INTERVENTIONAL

Solid Tumor Malignancies Brain Metastases From Solid Tumors

Start date: 2023-11-02
Primary completion: 2027-01-28
Enrollment: 86

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.